228 related articles for article (PubMed ID: 28165585)
41. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.
Mousa DH; Abdalla AH; Al-Shoail G; Al-Sulaiman MH; Al-Hawas FA; Al-Khader AA
Transplant Proc; 2004; 36(6):1831-4. PubMed ID: 15350490
[TBL] [Abstract][Full Text] [Related]
42. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
[TBL] [Abstract][Full Text] [Related]
43. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
[TBL] [Abstract][Full Text] [Related]
44. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
[TBL] [Abstract][Full Text] [Related]
45. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
46. Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL
J Clin Virol; 2017 Jul; 92():32-38. PubMed ID: 28521211
[TBL] [Abstract][Full Text] [Related]
47. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms.
Gordon CE; Uhlig K; Lau J; Schmid CH; Levey AS; Wong JB
Am J Kidney Dis; 2008 Feb; 51(2):263-77. PubMed ID: 18215704
[TBL] [Abstract][Full Text] [Related]
48. Detection, Reporting, and Treatment of Hepatitis C Infections Among Hemodialysis Patients.
Collier MG; Nguyen DB; Patel PR; Moorman AC
Infect Control Hosp Epidemiol; 2017 Apr; 38(4):493-494. PubMed ID: 28052785
[No Abstract] [Full Text] [Related]
49. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
50. Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease.
Ridruejo E; Mendizabal M; Silva MO
Hemodial Int; 2018 Apr; 22 Suppl 1():S97-S103. PubMed ID: 29694730
[TBL] [Abstract][Full Text] [Related]
51. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
52. Complexities of HCV management in the new era of direct-acting antiviral agents.
Rosenberg WM; Tanwar S; Trembling P
QJM; 2014 Jan; 107(1):17-9. PubMed ID: 24065837
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
54. Hepatitis C virus in chronic dialysis patients.
Natov SN; Pereira BJ
Minerva Urol Nefrol; 2005 Sep; 57(3):175-97. PubMed ID: 15986016
[TBL] [Abstract][Full Text] [Related]
55. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Miyazaki R; Miyagi K
Ther Apher Dial; 2016 Oct; 20(5):462-467. PubMed ID: 27098678
[TBL] [Abstract][Full Text] [Related]
56. Diagnostic discordance for hepatitis C virus infection in hemodialysis patients.
Kalantar-Zadeh K; Miller LG; Daar ES
Am J Kidney Dis; 2005 Aug; 46(2):290-300. PubMed ID: 16112048
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C eradication: A long way to go.
Waheed Y
World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
[TBL] [Abstract][Full Text] [Related]
58. Treating Hepatitis C in Patients with Renal Failure.
Lens S; Rodriguez-Tajes S; Llovet LP; Maduell F; LondoƱo MC
Dig Dis; 2017; 35(4):339-346. PubMed ID: 28467997
[TBL] [Abstract][Full Text] [Related]
59. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.
Hu TH; Su WW; Yang CC; Yang CC; Kuo WH; Chen YY; Yeh YH; Chen SS; Tsao YY; Chen KM; Yan SL; Lai JH; Yao CD; Lim CH; Jen HH; Yeh YP; Chen SL; Chen HH; Chen SC;
Am J Kidney Dis; 2021 Oct; 78(4):511-519.e1. PubMed ID: 33940114
[TBL] [Abstract][Full Text] [Related]
60. [Hepatitis C virus and chronic progressive kidney disease. Guidelines for detection, evaluation, treatment and prevention of infection transmission in hemodialysis units; procedure for infected patients-candidates for kidney transplantation and procedure for patients suspected of HCV infection-related kidney disease].
Kes P; Slavicek J;
Acta Med Croatica; 2013 Oct; 67(4):361-6. PubMed ID: 24984337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]